The available evidence suggests that combination immunotherapy using programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) inhibitors may be a promising treatment option for metastatic triple-negative breast cancer (mTNBC) (7). Here, PDCD1 is linked to triple-negative breast carcinoma.